Cerevasc has announced two new appointments to the company’s board of directors. Shlomi Nachman, former company group chairman of Cardiovascular and Specialty Solutions and Vision Groups within Johnson & Johnson’s Medical Devices sector, and Timothy Scannell, former president and chief operating officer (COO) of Stryker, will join Cerevasc as directors—effective 11 July 2024.
“We are excited to welcome Shlomi and Tim to the Cerevasc board,” said Dan Levangie, the company’s chairman and chief executive officer. “They both bring a wealth of experience in the medical device and neurovascular fields, and have distinguished careers in leading prominent medical device organisations. We look forward to leveraging their expertise and insights to bring the eShunt system to the market.”
Nachman has over 25 years of experience in the medical device industry and is currently on the board of several medical device companies, as well as the Arnold and Mable Beckman Foundation—a foundation focused on supporting research in chemistry and life sciences.
Previously, he held senior operating roles at Johnson & Johnson, where he was the company group chairman of Cardiovascular and Specialty Solutions and Vision Groups within Johnson & Johnson’s Medical Devices sector. Prior to that, Nachman had various roles with increased scope and responsibilities, including worldwide president of Biosense Webster and Cordis.
He earned his Bachelor of Science in management and economics from the Israel Institute of Technology (Haifa, Israel) and a diploma in electrical engineering from the Amal Technical School in Israel.
Scannell brings over 30 years of experience and success delivering market-leading results from his leadership roles at Stryker Corporation, one of the world’s leading medical technology companies. Scannell served as president and COO of Stryker between 2018–2021, overseeing all of the company’s commercial businesses and regions globally. Prior to this, he served as group president for Stryker’s MedSurg and Neurotechnology businesses for 10 years.
Scannell currently serves as a director and non-executive chairman of the board of directors for Insulet Corporation, and is a director on the boards of Novocure, Synaptive Medical, Regenity Biosciences and Molekule. He holds a Bachelor of Business Administration and a Master of Business Administration from the University of Notre Dame (Notre Dame, USA).
